<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimalarial regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimalarial regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimalarial regimens for treatment of uncomplicated non-falciparum malaria in nonpregnant adults and children*</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Pediatric dose (not to exceed adult dose)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preferred regimens<sup>¶</sup></td> </tr> <tr> <td class="indent1"><strong>Artemisinin combination therapy</strong></td> <td>Regimens and doses summarized in separate table</td> <td>Regimens and doses summarized in separate table</td> </tr> <tr> <td class="indent1"><strong>Chloroquine</strong><sup>Δ</sup></td> <td> <p><strong>Doses 1 and 2 (2<sup>nd</sup> dose administered at 24 hours):</strong> 1000 mg salt (= 600 mg base) orally</p> <p><strong>Dose 3 (3<sup>rd</sup> dose administered at 48 hours):</strong> 500 mg salt (= 300 mg base) orally per dose</p> (Total dose: 2500 mg salt [= 1500 mg base])</td> <td> <p><strong>Doses 1 and 2 (2<sup>nd</sup> dose administered at 24 hours):</strong> 16.7 mg salt/kg (10 mg base/kg) orally</p> <p><strong>Dose 3 (3<sup>rd</sup> dose administered at 48 hours):</strong> 8.3 mg salt/kg (5 mg base/kg) orally per dose</p> (Total dose: 41.6 mg salt/kg [25 mg base/kg]; maximum total dose: 2500 mg salt [= 1500 mg base])</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alternative regimens</td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace"><strong>Hydroxychloroquine</strong><sup>Δ◊</sup></span></td> <td> <p><strong>Doses 1 and 2 (2<sup>nd</sup> dose administered at 24 hours):</strong> 800 mg salt (= 620 mg base) orally</p> <p><strong>Dose 3 (3<sup>rd</sup> dose administered at 48 hours):</strong> 400 mg salt (= 310 mg base) orally per dose</p> (Total dose: 2000 mg salt [= 1550 mg base])</td> <td> <p><strong>Doses 1 and 2 (2<sup>nd</sup> dose administered at 24 hours):</strong> 12.9 mg salt/kg (10 mg base/kg) orally</p> <p><strong>Dose 3 (3<sup>rd</sup> dose administered at 48 hours):</strong> 6.5 mg salt/kg (= 5 mg base/kg) orally per dose</p> (Total dose: 32.4 mg salt/kg [25 mg base/kg]; maximum total dose 2000 mg salt [= 1550 mg base])</td> </tr> <tr> <td class="indent1"> <p><span class="nowrap_whitespace"><strong>Atovaquone-proguanil</strong><sup>§</sup></span></p> <p>Adult tab = 250 mg atovaquone/100 mg proguanil</p> Pediatric tab = 62.5 mg atovaquone/25 mg proguanil</td> <td>4 adult tabs orally once daily for 3 days</td> <td> <p>5 to &lt;8 kg: 2 pediatric tabs orally once daily for 3 days</p> <p>8 to &lt;10 kg: 3 pediatric tabs orally once daily for 3 days</p> <p>10 to &lt;20 kg: 1 adult tab orally once daily for 3 days</p> <p>20 to &lt;30 kg: 2 adult tabs orally once daily for 3 days</p> <p>30 to &lt;40 kg: 3 adult tabs orally once daily for 3 days</p> ≥40 kg: 4 adult tabs orally once daily for 3 days</td> </tr> <tr> <td class="indent1" rowspan="2"> <p><span class="nowrap_whitespace"><strong>Quinine sulfate</strong><sup>¥</sup></span></p> <strong>Plus</strong> one of the following:</td> <td> <p><strong>United States:</strong> Quinine sulfate 648 mg salt<sup>¥</sup> (= 538 mg base) orally 3 times daily for 3 or 7 days<sup>†</sup></p> <strong>Canada, European Union, United Kingdom:</strong> Quinine sulfate 600 mg salt<sup>¥</sup> (= 500 mg base) orally 3 times daily for 3 or 7 days<sup>†</sup></td> <td>Quinine sulfate:<sup>¥</sup> 10 mg salt/kg (= 8.3 mg base/kg) orally 3 times daily for 3 or 7 days<sup>†</sup></td> </tr> <tr> <td><strong>Plus</strong> one of the following:</td> <td><strong>Plus</strong> one of the following:</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li><span class="nowrap_whitespace"><strong>Doxycycline</strong><sup>‡</sup>,</span></li> </ul> </td> <td> <ul class="decimal_heading"> <li>Doxycycline: 100 mg orally twice daily for 7 days</li> </ul> </td> <td> <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Doxycycline:<sup>‡</sup></span> 2.2 mg/kg orally every 12 hours for 7 days</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li><span class="nowrap_whitespace"><strong>Tetracycline</strong><sup>‡</sup>, or</span></li> </ul> </td> <td> <ul class="decimal_heading"> <li>Tetracycline: 250 mg orally four times daily for 7 days</li> </ul> </td> <td> <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Tetracycline:<sup>‡</sup></span> 6.25 mg/kg orally every 6 hours for 7 days</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li><strong>Clindamycin</strong></li> </ul> </td> <td> <ul class="decimal_heading"> <li>Clindamycin: 20 mg/kg/day (up to 1.8 g) orally divided 3 times daily for 7 days</li> </ul> </td> <td> <ul class="decimal_heading"> <li>Clindamycin: 20 mg/kg/day (up to 1.8 g) orally divided 3 times daily for 7 days</li> </ul> </td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace"><strong>Mefloquine</strong>**</span></td> <td> <p>500 mg salt (= 456 mg base) orally once daily for 3 days <strong>or</strong> 8 mg salt/kg (= 7.3 mg base/kg) orally once daily for 3 days, whichever is less.</p> (Total maximum dose: 1500 mg salt [= 1369 mg base] in equally divided doses over 3 days)</td> <td> <p>8 mg salt/kg (= 7.3 mg base/kg) orally once daily for 3 days; maximum 500 mg salt (= 456 mg base) per dose</p> (Total dose: 24 mg salt/kg (= 22 mg base/kg); maximum 1500 mg salt [= 1369 mg base] in equally divided doses over 3 days)</td> </tr> </tbody></table></div><div class="graphic_lgnd">The dosing regimens listed in this table are generally consistent with the CDC guidelines for the treatment of uncomplicated malaria in the United States and may differ from dosing recommended in approved product information. Product availability varies by locality.</div><div class="graphic_footnotes"><p>CDC: United States Centers for Disease Control and Prevention; G6PD: glucose-6-phosphate dehydrogenase; ACT: artemisinin combination therapy; WHO: World Health Organization.</p>
<p>* For treatment of infection due to <em>Plasmodium vivax</em> and <em>Plasmodium ovale</em>, presumptive antirelapse therapy to eradicate the hypnozoite liver stages should be administered after normal G6PD status has been confirmed; options for antirelapse therapy include primaquine or tafenoquine. Refer to the UpToDate topics for further discussion.</p>
<p>¶ The approach to antimalarial selection depends on a number of factors including species diagnosis and likelihood of chloroquine resistance. Preferred regimens for treatment of chloroquine-sensitive non-falciparum malaria consist of chloroquine or ACT. Preferred regimens for treatment of chloroquine-resistant non-falciparum malaria consist of ACT. If an antimalarial is taken for chemoprophylaxis, a different drug should be used for treatment.</p>
<p>Δ In the United States and Canada, pill strengths for chloroquine and hydroxychloroquine are labeled in salt; in many other countries, pill strengths are labeled in base. 250 mg chloroquine phosphate (salt) is equivalent to 150 mg chloroquine base; 200 mg hydroxychloroquine sulfate (salt) is equivalent to 155 mg hydroxychloroquine base.</p>
<p>◊ Hydroxychloroquine is appropriate only for treatment of chloroquine-susceptible infection.</p>
<p>§ Take with food or whole milk. If the patient vomits within 30 minutes of taking a dose, then they should repeat the dose. It is also acceptable to take one-half of the dose twice daily.</p>
<p>¥ In the United States and Canada, pill strengths for quinine are labeled as quinine sulfate (salt); in many other countries, pill strengths are labeled in quinine base. 324 mg quinine sulfate (salt) = 269 mg quinine base. Pediatric dosing may require compounding pharmacy, since noncapsule forms of quinine are not available in the United States.</p>
<p>‡ Tetracycline antibiotics may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, doxycycline binds less readily to calcium than other tetracyclines and may be used for ≤21 days in children of all ages.<sup>[1]</sup></p>
<p>† For infections acquired in Southeast Asia, quinine treatment should continue for 7 days. For infections acquired elsewhere, quinine treatment should continue for 3 days.</p>
    
    ** Mefloquine should be used only if other options are not available, and it is not recommended for children &lt;15 kg or in patients with neuropsychiatric history. The dosing regimen for mefloquine outlined above is in alignment with the WHO<sup>[2]</sup>, which differs from the CDC approach; the WHO approach is associated with greater bioavailability and is better tolerated<sup>[3]</sup>. In the United States and Canada, pill strengths for mefloquine are labeled in hydrochloride salt; in many other countries, pill strengths are labeled in mefloquine base. 250 mg mefloquine hydrochloride (salt) is equivalent to 228 mg mefloquine base.</div><div class="graphic_reference">References:
    <ol>
<li>American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li>
<li>WHO Guidelines for malaria, 3 June 2022. Geneva: World Health Organization. <a href="https://www.who.int/publications/i/item/guidelines-for-malaria" target="_blank">https://www.who.int/publications/i/item/guidelines-for-malaria</a>.</li>
<li>Lee SJ, Ter Kuile FO, Price R et al. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19,850 individual patients. PLoS One 2017;12:1.</li>
</ol>
<p class="extra_spacing_top">Adapted from: United States Centers for Disease Control and Prevention. Guidelines for Treatment of Malaria in the United States: https://www.cdc.gov/malaria/resources/pdf/malaria_treatment_table_202302c.pdf (Accessed on September 5, 2023). CDC Malaria Hotline: (770) 488-7788 Monday to Friday 8:00 am to 4:30 pm EST; (770) 488-7100 after hours, weekends, and holiday.</p></div><div id="graphicVersion">Graphic 107829 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
